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Abstract Hypertension is a complex trait with deranged
autonomic control of the circulation. The sympathoadrenal
system exerts minute-to-minute control over cardiac output
and vascular tone. Catecholamine storage vesicles (or
chromaffin granules) of the adrenal medulla contain
remarkably high concentrations of chromogranins/secretog-
ranins (or “granins”), catecholamines, neuropeptide Y,
adenosine triphosphate (ATP), and Ca
2+. Within secretory
granules, granins are co-stored with catecholamine neuro-
transmitters and co-released upon stimulation of the
regulated secretory pathway. The principal granin family
members, chromogranin A (CHGA), chromogranin B
(CHGB), and secretogranin II (SCG2), may have evolved
from shared ancestral exons by gene duplication. This
article reviews human genetic variation at loci encoding the
major granins and probes the effects of such polymor-
phisms on blood pressure, using twin pairs to probe
heritability and individuals with the most extreme blood
pressure values in the population to study hypertension.
Keywords Genetics.Hypertension.Catecholamine.
Granins.Blood pressure.CHGA.CHGB.SCG2.
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Introduction: The Sympathoadrenal System
and Granins
The sympathoadrenal system exerts minute-to-minute con-
trol over cardiac output and vascular tone. Genes governing
catecholaminergic processes may play a role in the
development of hypertension. Catecholamine storage
vesicles (or chromaffin granules) of the adrenal medulla
(Fig. 1) contain remarkably high concentrations of chro-
mogranins/secretogranins (“granins”), neuropeptide Y
(NPY), catecholamines, adenosine triphosphate (ATP), and
Ca
2+. Within the vesicle core, granins bind catecholamines
and ATP, to stabilize the core osmotically [1, 2]. When the
major granin, chromogranin A (CHGA), is depleted by
gene targeting, adrenal chromaffin granules are reduced in
number, size, and electron density, and transmitter secretion
from the regulated pathway is disrupted [3]. Granins also
bind to the inner aspect of the vesicle membrane, where
they may influence the release of calcium from secretory
granules to the cytosolic exocytotic machinery through the
inositol 1,4,5-trisphosphate receptor/Ca
2+ channel [4].
CHGA, chromogranin B (CHGB), and secretogranin II
(SCG2) are paralogous genes that likely arose by gene
duplication within the vertebrate lineage [5], suggesting
closely related cellular and physiological functions. Heter-
ologous expression of any one of the three “granins” is
sufficient to induce secretory granules and regulated
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DOI 10.1007/s11906-010-0170-ysecretion in cells that otherwise lack both [6–8], and depletion
of endogenous CHGA impairs formation of chromaffin
granules in PC12 chromaffin cells [3]. Within secretory
granules, granins are co-stored with catecholamine neuro-
transmitters and are co-released upon stimulation of regulated
secretion. Information on chromosomal positions, genomic
structure, cDNA, and proteins encoded by the three genes is
displayed in Table 1.
Proteolytic cleavage of granins at dibasic sites generates an
array of bioactive peptides within secretory vesicles. In
aggregate, these peptides have physiological effects on
cardiovascular, endocrine, metabolic, and immune systems
throughbothdirectandindirectparticipationofthesympathetic
nervous system [9]. CHGA is a pro-hormone that gives rise to
at least four biologically active fragments: the dysglycemic
peptide pancreastatin [10, 11]; the antimicrobial peptide
chromacin [12]; the amino-terminal vasodilator vasostatin
[13]; and the catecholamine release inhibitor catestatin [14,
15]. As a pro-protein, CHGB is cleaved to biologically active
fragments including “GAWK” [16, 17] (bovine Chgb398–464,
human CHGB420–493), “CCB” [16] (human CHGB597–656),
“PE-11” [18] (rat Chgb532–542, human CHGB536–545), and the
endogenous antimicrobial/bacteriolytic peptides chrombacin
[19] (bovine Chgb564–626, human CHGB597–657) and secreto-
lytin [20] (bovine Chgb614–626, human CHGB647–657). SCG2
is the precursor of the 33–amino acid peptide secretoneurin
(SN, human SCG2165–187), which modulates neurotransmis-
sion and inflammatory responses and may be involved in
neuronal differentiation [21].
This review first considers the cellular and physiological
mechanisms of granin action that relate to sympathoadrenal
regulation, and then reviews recent findings on associations
Fig. 1 Intracellular and extracellular chromogranin/secretogranin
actions. Chromaffin granule transmitter storage and exocytotic release
are depicted, with secretion in response to the preganglionic trans-
mitters acetylcholine (Ach) or pituitary adenylyl cyclase activating
polypeptide (PACAP). Catestatin, the endogenous nicotinic choliner-
gic antagonist (ganglionic-blocking) peptide fragment of CHGA,
inhibits the principal physiological trigger of chromaffin cell secretory
stimulation: the nicotinic cholinergic pathway. ATP—adenosine
triphosphate; CHGA—chromogranin A; CHGB—chromogranin B;
nAchR—nicotinic cholinergic receptor; NPY—neuropeptide Y;
PAC1R—PACAP type 1 receptor; SCG2—secretogranin II. (Adapted
from Mahapatra et al. [1])
Table 1 Genomic structure of classic/major human chromogranin/secretogranins: CHGA, CHGB, and SCG2
Gene Chromosome Chromosomal position Genomic size (bp) cDNA (bp) Exons Amino acids Signal peptide Molecular weight (Da)
CHGA 14q32 93389445–93401636 12,192 2,079 8 457 1–18 48,918
CHGB 20p12.3 5891974–5906003 14,030 2,666 5 677 1–20 76,326
SCG2 2q36.1 224461660–224467121 5,462 2,490 2 617 1–27 70,810
Bp base pairs; Da Daltons
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intermediate phenotypes that may underlie susceptibility to
hypertension.
Granin Secretion and Hypertension
CHGA
Basal plasma CHGA concentration is correlated with sympa-
thetic tone [22, 23], and studies in twins indicate that the
basal level is highly heritable [24]. As compared with age-
matched normotensive controls, patients with essential
hypertension have increased plasma CHGA and an increased
release of stored CHGA in response to adrenal medullary
stimulation by insulin-evoked hypoglycemia [24]. The
dysglycemic CHGA fragment pancreastatin is also elevated
in patients with essential hypertension with or without
obesity [25, 26]; its actions may therefore contribute to the
insulin resistance that often accompanies the condition.
Catestatin, the CHGA–derived peptide that inhibits catechol-
amine release, is decreased in patients with essential
hypertension and even in normotensive subjects with a
family history of hypertension [27]. Moreover, people with
such a family history have increased epinephrine secretion in
addition to diminished catestatin, suggesting an inhibitory
effect of catestatin on chromaffin cells in vivo. Low catestatin
levels also predict augmented adrenergic response to
stressors, suggesting that reduction in catestatin increases
risk of hypertension [27]. The catestatin Gly364Ser variant
causes profound changes in human autonomic activity, both
parasympathetic and sympathetic, and seems to reduce risk
of developing hypertension, especially in men. A model for
catestatin action in the baroreceptor center of the nucleus of
the tractus solitarius accounts for these actions [28].
Consistent with these findings in humans, expression of the
Chga gene was observed to be significantly higher in adrenal
glands of rat and mouse models of genetic hypertension [29–
31], supporting the phenotypic association between elevated
CHGA and essential hypertension.
CHGB
Expression of CHGB may mark the action of still poorly
characterized trans-quantitative trait loci influencing exocy-
totic sympathoadrenal activity [32, 33]. Like CHGA, CHGB
may be differentially expressed in rodent models of genetic
hypertension [29, 30] and acquired hypertension [34], further
suggesting augmented sympathoadrenal activity in the
pathogenesis of these syndromes. CHGB may thereby give
rise to early, pathogenic “intermediate phenotypes” [35]f o r
exploration of sympathoadrenal activity in human essential
hypertension.
SCG2
The secretoneurin peptide derived from SCG2 (human
SCG2165–187) stimulates migration and proliferation of
vascular smooth muscle cells [21] and acts as an endothelial
cytokine to promote angiogenesis and vasculogenesis [30,
36], providing a direct link to vascular development and
remodeling and a potential model for its involvement in
autonomic phenotypes.
Population Samples and Traits for Genetic Studies
of Hypertension: Mechanism and Risk
Twin and Sibling Pairs
Applying a classic twin design in the search for trait-
associated polymorphisms [37], multiple autonomic pheno-
types were measured in twin pairs, permitting estimation of
trait heritability and definition of effects of particular
genetic variants on “intermediate” (early, pathogenic)
phenotypes; simultaneous documentation of heritability
and association lends internal validation to the approach.
Twins in such allelic/haplotype association studies were
self-identified as being of European (white) ancestry, to
minimize effects of population stratification.
Blood Pressure Change During Cold Stress: Heritable
“Intermediate” Phenotype of Hypertension
Because systemic hypertension may result from the cumula-
tive effects of transient adverse blood pressure (BP) responses
to environmental stress in genetically predisposed individuals
[38], we probed the BP response to environmental stress,
using cold as a systematic stimulus in a series of predom-
inantly normotensive twin pairs. Stress BP increments were
significantly heritable (h
2=32±8%, P=0.0003 for change in
diastolic BP [DBP]; h
2=23±9%, P=0.0098 for change in
systolic BP [SBP]), as estimated by twin pair variance
components [39].
Population Sample With Extreme BP Values: A Statistically
Powerful Sample for Association Studies of Hypertension
To pursue the genetic involvement in established essential
hypertension, we developed a powerful resource in the form
of a population-based sample consisting of individuals with
extremely high and low BPs [40]. From a primary care
practice sample of over 53,000 people, we ascertained more
than 1,000 individuals from the upper and lower 5th
percentiles of the population BP distribution, matched for
age, gender, and ethnicity [41].
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Open Reading Frame
During resequencing, three variants were discovered in the
catestatin region, the most common of which was Gly364Ser,
at ~3.1% of the initial ~360 chromosomes resequenced [42]. In
cultured hippocampal neurons, wild-type human catestatin
(SSMKLSFRARAYG364FRGPGPQL) inhibited nicotinic
cholinergic-stimulated catecholamine release completely (to
0.3±2.8% of control) at 10 μm o l / L .T h es a m ed o s eo ft h e
364Ser variant (SSMKLSFRARAYS364FRGPGPQL)
inhibited catecholamine release with substantially reduced
potency: 35.7±3.1% of control secretion persisted [28].
Carriers of 364Ser had diminished renal norepinephrine
excretion (by ~26%; P=0.047) and epinephrine excretion
(by ~34%; P=0.003); plasma norepinephrine also declined
by ~36% (P=0.019), though plasma epinephrine was un-
changed [28]. Gly/Ser heterozygotes displayed increased
baroreceptor slope during upward deflections (by ~47%) and
downward deflections (by ~44%), increased cardiac parasym-
pathetic index (by ~2.4-fold), and decreased cardiac sympa-
thetic index (by ~26%). The 364Ser variant was associated
with lower diastolic blood pressure in two independent/
confirmatory groups of patients with hypertension (UCSD
unrelated, n=489; population with blood pressure extreme
values, n=1361); genotype groups differed by ∼5–6m mH g ,
and the polymorphism accounted for ∼1.8% of population
diastolic blood pressure variance, although a significant gene-
by-sex interaction existed, with an predominant effect in men.
Promoter: CHGA Promoter Haplotype Effects on Stress
Traits
Five tightly linked common promoter variants—at positions C-
1014T (rs9658630), G-988T (rs9658631), G-462A
(rs9658634), C-415T (rs9658635), and A-89C (rs7159323)—
were investigated in a study of 112 phenotyped twin pairs
(2n=224 individuals), and haplotypes were inferred with the
HAP algorithm, a method for haplotype resolution from
genotype data [43]. The three most common haplotypes,
TTGTC (Hap-A, 56.9%), CGATA (Hap-B, 23.0%), and
TTGCC (Hap-C, 16.5%), accounted for more than 95% of
all haplotypes. Diploid haplotypic variation in the region
affected both the change in DBP (P=0.0222) and the final
DBP (P=0.0167) during cold stress [44•]. Homozygosity for
Hap-B (CGATA/CGATA) seemed to blunt both the change in
DBP and the final DBP, whereas Hap-A/Hap-B heterozygos-
ity (TTGTC/CGATA) was associated with the greatest values
of both the change in DBP and the final DBP. The more
extreme trait values for heterozygotes (as compared with
either homozygote class) suggested the phenomenon of
molecular heterosis [45].
CHGA 3′-UTR Variant C+87T (rs7610) and Dichotomous
(Hypertension) as well as Continuous (mm Hg) BP Traits
Table 2a indicates the C+87T genotype effect in men (P=
0.004) and lack of effect in women (P=0.262). To focus on
the role of the minor (T) allele, we combined the minor allele
homozygote (T/T) with heterozygote (C/T) categories, and
compared them with C/C (major allele) homozygotes. The C
allele displayed a significant effect on blood pressure in men
but not in women [46•].
Table 2b shows the effects of C+87T on SBP and DBP as
continuous traits (in mm Hg). Even though these individuals
were ascertained from the population by a DBP criterion [41],
those who were hypertensive exhibited elevations of both
DBP and SBP, and there were significant effects of C+87T
genotype on both SBP (P=0.028) and DBP (P=0.037).
Likewise, there were significant genotype-by-sex interactions
on both SBP (P=0.015) and DBP (P=0.010). In men, BP
differences between homozygote (C/C, T/T) classes were
substantial: ∼12 mm Hg for SBP and ∼9m mH gf o rD B P .B y
ANOVA (adjusted) R
2 in men, C+87T accounted for ∼1.9%
of the population variance in SBP (or ∼13.7 mm Hg),
and ∼1.2% of the variance for DBP (or ∼5.8 mm Hg). In
women, C+87T did not affect either SBP or DBP.
CHGB and Blood Pressure
CHGB Promoter Variants A-296C and A-261T: Implications
for Hypertension
There are two common single nucleotide polymorphisms
(SNPs) in the proximal promoter of human CHGB: A-296C
(rs236140) and A-261T (rs236141). Promoter haplotype
effects upon BP in the population were highly significant
(Fig. 2)[ 47•]. Chromosome-based haplotype analysis on
individuals dichotomized into two groups (higher versus
lower BP) indicated that individuals with the less common
AT or CA haplotypes had a strong tendency to be
hypertensive (OR=4.898 for AT haplotype, P=3.19E-11;
OR=3.84 for CA haplotype, P=3.64E-10). People with the
more common haplotype CT had a strong tendency to be
normotensive (OR=0.637; 95% CI, 0.524–0.773; P=
4.64E-6). The most common haplotype, AA, had no effect
on BP status. The overall effect of CHGB haplotypes on BP
status was substantial, as shown on Fig. 2,w h e t h e r
analyzed by chromosome/haplotype (global χ
2=93.9, P=
3.16E-20) (left panel) or by diploid haplotype pairs (global
χ
2=75.0, P=4.92E-13) (right panel).
We also studied the quantitative trait effects (SBP and DBP
in mm Hg) of CHGB haplotypes, and found substantial
predictions for both SBP and DBP. With increasing copy
number (0→1→2) of haplotype AT, SBP increased
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by ∼21 mm Hg (P=1.59E-5), each in additive fashion. With
increasing copy number of haplotype CA, SBP increased
by ∼13 mm Hg (P=0.005) and DBP increased
by ∼12 mm Hg (P=8.49E-6). With increasing copy number
of haplotype CT, SBP decreased by ∼11 mm Hg (P=0.0045),
with a parallel decrease in DBP by ∼7m mH g( P=0.011).
When we adjusted BP values for the effects of antihyperten-
sive medications in treated hypertensives [48], the haplotype
effects on SBP/DBP persisted or increased: AT, P=4.1E-5/
P=6.83E-6; CA, P=0.008/P=2.04E-5; CT, P=0.002/
P=0.008.
Promoter polymorphisms A-296C/A-261T interacted
nonadditively to influence SBP and DBP (P=1.15E-6/P=
Table 2 CHGA 3′-UTR common variant C+87T and BP. Effect of the T allele on blood pressure status and values
a
Sex Genotype
a. CHGA C+87T genotype frequencies and BP status (dichotomized)
b
High BP, n Low BP, nP (2-sided)
Male C/C 156 107
C/T or T/T 95 112 0.004
Female C/C 112 170
C/T or T/T 119 148 0.262
b. CHGA C+87T genotype and BP as a continuous trait
c
SBP (mm Hg) DBP (mm Hg)
Male C/C 137.2±1.6 83.7±1.3
C/T or T/T 131.2±1.8 77.6±1.5
Male ANOVA P value 0.016 0.003
Female C/C 123.8±1.7 71.8±1.2
C/T or T/T 126.9±1.7 73.8±1.3
Female ANOVA P value 0.206 0.272
Reprinted from Journal of the American College of Cardiology, Vol. 52. Chen Y, Rao F, Rodriguez-Flores JL, et al.: Naturally occurring human
genetic variation in the 3′-untranslated region of the secretory protein chromogranin A is associated with autonomic blood pressure regulation and
hypertension in a sex-dependent fashion; Pages 1468–1481, Copyright 2008, with permission from Elsevier
ANOVA analysis of variance; BP blood pressure; DBP diastolic blood pressure; SBP systolic blood pressure; UTR untranslated region
aSubjects are grouped by absence (C/C) or presence (T/T or C/T) of the T (minor) allele
bResults evaluated by chi-square test
cAllelic association (presence or absence of the T allele) evaluated by univariate ANOVA
   
Fig. 2 Prediction of blood pressure (BP) status by CHGB promoter
haplotypes in a population (of European ancestry) with BP extremes.
Haplotypes (or haplotype pairs) are ordered by rank of association
with elevated BP. Left: Haplotype (chromosome) effects. Right:
Haplotype pair (diploid haplotype) effects. The two most common
haplotypes (AA and CT) are more frequent in individuals with lower
BP, whereas the two less common haplotypes (CA and AT) are more
frequent in those with higher BP. CHGB—chromogranin B; HT—
hypertensive; NT—normotensive. (Adapted from Zhang et al. [47•])
40 Curr Hypertens Rep (2011) 13:36–451.07E-10). On a background of A-296C major allele
homozygosity (A/A), the A-261T major (A) allele lowered
SBP/DBP by ∼27/∼22 mm Hg, whereas on a background
of A-296C minor allele homozygosity (C/C), the A-261T
major (A) allele elevated SBP/DBP by ∼21/∼18 mm Hg.
When treatment-adjusted BPs [48] were analyzed, the
interactions increased or persisted: SBP/DBP, P=4.41E-7/
P=1.08E-10. The A-296C-by-A-261T (SNP-by-SNP) in-
teraction was confirmed on analyses of the dichotomous BP
trait (higher vs lower): P=3.71E-15.
SBP/DBP values stratified by CHGB promoter haplotypes
were, in rank order: CT<AA<<CA<AT (SBP/DBP, P=
6.16E-8/P=5.18E-12). On ANOVA, CHGB promoter genet-
ic variation accounted for ∼2.3% of SBP variance and ∼3.4%
of DBP variance in this primary care population.
Parallel Effects of Human CHGB Promoter Haplotypes
In Vivo and in Cells
To probe the functional significance of the two common
promoter variants for transcriptional efficiency, we inserted
each of the four haplotypes (across A-296C and A-261A) into
the luciferasereporter plasmid pGL3-Basic. After transfection
intoratchromaffin(PC12)cells,these fourhaplotypesyielded
substantially different luciferase reporter activity. Site-specific
analysis of reporter activity showed that both A-296C and A-
261T have context-dependent actions. The transcriptional
strengths of combinations of A-296C and A-261T were
AT>CT>AA>CT (P=8.46E-07). By two-way ANOVA,
overall F=107.2, P=8.46E-07; A-296C, P=2.09E-05; A-
261T, P=0.064; 296-by-261 interaction, P=3.07E-07. The
four promoter haplotypes displayed the same rank order for
effects on BP in vivo and for luciferase reporter activity in
chromaffin cells.
“Intermediate” Traits: Association of CHGB Promoter
Variants A-296C and A-261T
In 163 white twin pairs who were predominantly (∼90%)
normotensive, the DBP response to environmental (cold)
stress was substantially heritable (h
2=32±8%, P=0.0003)
[49]. CHGB promoter individual genotypes A-296C (A>C,
P=0.0237) and A-261T (A>T, P=0.037) predicted the
change in DBP in the cold stress test. Because of the
modest sample size (2n=326 chromosomes), we observed
only five examples of the CA haplotype and one of the AT
haplotype, so analyses could only be performed for
haplotypes AA and CT. Consistent with basal BP in white
BP extremes, the CT haplotype decreased the change in
DBP in response to stress, whereas the AA haplotype
increased it; thus, the rank order of effects of the haplotypes
on BP was preserved in twins (AA>CT), though the effects
of the more prominent BP-increasing haplotypes (CA, AT)
could not be quantified in this predominantly normotensive
sample.
CHGB 3′-UTR Common Variant C+84A (rs2821),
Isoprostane, and Hypertension
Isoprostane marks oxidative stress, and elevated isoprostane
excretion may be involved in cardiovascular target organ
damage. Urinary isoprostane excretion was substantially
heritable in twin pairs (h
2=65.8±4.3%), and the isoprostane
trait aggregated with multiple traits (CHGB, catecholamines,
autonomic/baroreceptor sensitivity, and renal function),
including several features of the metabolic syndrome (body
mass index, insulin resistance, dyslipidemia). Isoprostane
excretion also paralleled systemic hypertension. A common
variant in the 3′-untranslated region (UTR) of CHGB
(C+84A, rs2821) associated with plasma CHGB and
isoprostane excretion. C+84A disrupted an A/U-rich mRNA
stability element, and in transfected luciferase/3′-UTR
plasmids, the C+84 and +84A alleles differed markedly in
reporter expression in chromaffin and neuroblastoma cells;
site-directed mutagenesis confirmed the importance of this
variant within the context of the A/U-rich motif [50•].
SCG2 and Blood Pressure
SCG2: A Functional Intronic Variant (G736A, rs1017448,
intron-1) Is Associated with Hypertension
At systematic polymorphism discovery at the SCG2 locus,
BP associations maximized at variant G736A (rs1017448)
in the sole intron; G736A is common (at ∼30.5%) only in
African Americans, and the minor allele A seemed to be
ancestral [51]. This SNP was investigated in five different
cohorts. G736A was associated with blood pressure in
African Americans from the University of California, San
Diego (UCSD) (n=383, P=0.0049), with the ancestral
allele (A) predicting increased risk for hypertension.
Significant association was observed in a second cohort of
unrelated African Americans from metropolitan San Diego
(n=465) for both recessive (P=0.022) and dominant (P=
0.0098) models. Taking the two case-control studies as
independent observations supports P∼10
−4 for either
dominant or recessive models. In African American
families from the GenNet network of the NHLBI Family
Blood Pressure Program (n=781), analysis shows associa-
tion of G736A with SBP (FBAT, P=0.032 under an
additive model) and pulse pressure (FBAT, P=0.0074
additive model; P=0.0076 for dominant or recessive
models), though not with hypertension diagnosis as a
dichotomous trait. However, two population samples with
extreme BPs—a Nigerian sample (n=370) and a European
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ciations, although the minor allele frequency among
European Americans was too low to be sufficiently
informative; indeed, we observed no minor allele homo-
zygotes among those 1,315 individuals.
Thus all three African American cohorts showed
significant association of the 736A allele with elevated
blood pressure or hypertension. A meta-analysis was
performed of unrelated individuals from all five cohorts,
and this analysis showed significant associations in both
additive models (P=0.017) and dominant models (P=
0.028), which survived correction for covariates.
Paired-like homeobox transcription factors PHOX2A
(ARIX) and PHOX2B were identified by oligonucleotide
affinity chromatography and mass spectrometry as potential
transactivating factors across the G736A motif; this finding
was confirmed by chromatin immunoprecipitation. Each of
these transcription factors preferentially binds the risk
allele, both in vitro and in vivo [51]. PHOX2A and
PHOX2B play roles in autonomic nervous system function;
these paralogous genes are expressed in a largely over-
lapping pattern during development [52], but genetic
studies point to unique requirements for each factor in vivo.
Hypertension Consequences: The Kidney
CHGA and Microalbumin Excretion
Urinary albumin excretion is a risk factor for adverse
cardiovascular events, and even albumin excretion values less
than those typically cited as constituting microalbuminuria or
incipient nephropathy may signal cardiovascular risk. Urinary
excretions of albumin and catecholamines were highly
heritable in twin pairs, and their parallel suggests adrenergic
mediation of early glomerular permeability alterations [53];
indeed, the heritability of albumin excretion was h
2=45.2±
7.4% (P=2×10
−7). In the same study, we found that albumin
excretion associated with polymorphisms at multiple points
in the adrenergic pathway: catecholamine biosynthesis,
catabolism, storage/release (CHGA), receptor targets, and
postreceptor signal transduction. At CHGA,a s s o c i a t i o n s
were found not only for haplotypes spanning the locus, but
also for functional catestatin variant Gly364Ser. Thus
interindividual variability in albumin excretion is controlled
in substantial part by genetic variation in the adrenergic
pathway, including common, naturally occurring polymor-
phism at the CHGA locus.
CHGA Genetic Variation and Hypertensive Renal Disease
Among blacks, we studied common genetic variants
spanning the CHGA locus in two independent case-control
studies of hypertensive end-stage renal disease (ESRD),
comprising 58 cases and 150 control subjects. Two
haplotypes were significantly more frequent among patients
with hypertensive ESRD: 1) in the promoter (5′) region, G-
462A (rs9658634) →T-415C (rs9658635) →C-89A
(rs7159323), haplotype ATC (adjusted OR=2.65; P=
0.037); and 2) at the 3′-end, C11825T (3′-UTR, C+87T;
rs7610) →G12602C (rs875395), haplotype TC (adjusted
OR=2.73, P=0.0196). Circulating levels of catestatin were
lower among those with hypertensive ESRD than among
controls, an unexpected finding given that peptide levels
are usually elevated in ESRD because of reduced renal
elimination [54•].
CHGA Regulates Renal Function by Triggering
Weibel–Palade Body Exocytosis From Endothelial Cells
In twin pairs, the CHGA locus is a trans-quantitative trait
locus for determination of endothelin-1 (ET-1) secretion,
with maximal association in the CHGA promoter region, and
the CHGA protein itself triggers ET-1 release from human
umbilical vein endothelial cells [55]. Weibel-Palade bodies
are the storage granules of endothelial cells. They store and
release two principal molecules, von Willebrand factor and
P-selectin, and thus play a dual role in hemostasis and
inflammation. CHGA led to the release of ET-1 and indeed
global Weibel–Palade body exocytosis in cultured human
umbilical vein endothelial cells, and the secretory effect
mapped onto the amino-terminal (vasostatin) region of the
molecule. In addition, CHGA triggered secretion of ET-
1from glomerular capillary endothelial cells and TGF-β1
from co-cultured mesangial cells. In humans, plasma CHGA
correlated positively with ET-1 and negatively with the
glomerular filtration rate (GFR). GFR was highly heritable in
twin pairs, and common promoter haplotypes of CHGA
predicted the GFR trait value. In patients with progressive
hypertensive renal disease, a CHGA haplotype predicted the
rate of GFR decline. Thus CHGA seems to act through the
glomerular endothelium to regulate renal function as well as
progressive renal disease [56•].
An Experimental Animal Model: Elevated BP
After Targeted Chromogranin Gene Ablation
in the Mouse
Chga-/- (knockout) mice displayed extreme phenotypic
changes, including: decreased chromaffin granule size and
number; elevated BP; loss of diurnal BP variation; increased
left ventricular mass and cavity dimensions; decreased
adrenal catecholamine, neuropeptide Y (Npy), and ATP
contents; increased catecholamine/ATP ratio in the chromaf-
fin granule; and increased plasma catecholamine and Npy
42 Curr Hypertens Rep (2011) 13:36–45levels. Rescue of elevated BP to normalcy was achieved by
either exogenous catestatin replacement or humanization of
Chga-/- mice. Loss of the physiological “brake” catestatin in
Chga-/- mice, coupled with dysregulation of transmitter
storage and release, may act in concert to alter autonomic
control of the circulation in vivo, eventuating in hypertension
[3]. The syndrome could be “rescued” by BAC (bacterial
artificial chromosome) haplotype replacement of the human
CHGA gene into the mouse knockout strain genome [3, 57•].
The Chga-/- mouse displays widespread derangements in
autonomic function, both sympathetic and parasympathetic
[58•], including diminished baroreceptor sensitivity to both
high-pressure and low-pressure stimuli and diminished heart
rate variability [59•]; each of these can be rescued by
replacementofthecatestatin(catecholaminereleaseinhibitory)
fragment of CHGA.
Later studies indicated that the relationship of the Chga
gene to BP may be even more complex, with a biphasic (or
U-shaped) dose/response curve for Chga gene copy number
and basal BP [57•] and parallel changes in adrenal
catecholamine storage and release. In this transgenic model,
titration of CHGA gene copy number was enabled by BAC
haplotype replacement and targeted breeding.
Finally, loss of pancreastatin in the Chga-/- mouse has
predictable metabolic consequences, including heightened
sensitivity of glucose disposal to endogenous or exogenous
insulin [60•, 61•]. The insulin-hypersensitive state is
reversed by replacement of the dysglycemic pancreastatin
fragment of CHGA [61•].
Similarly, Chgb-/- (knockout) mice display substantially
higher SBP and DBP (by ∼20/∼18 mm Hg) than Chgb+/+
mice [62•]. These mice have 36% less adrenomedullary
epinephrine when compared to wild-type mice, whereas the
norepinephrine content is similar. This decrease is not due
to a lower frequency of exocytotic events, but rather to less
secretion per quantum (∼30%) measured by amperometry;
amperometric spikes exhibit a slower ascending phase but a
normal decaying phase [63]. Chgb-/- animals display some,
but not all, hallmarks of human type 2 diabetes. Stimulated
secretion of insulin, glucagon, and somatostatin is reduced
in Chgb-/- islets, in parallel with somewhat impaired
glucose clearance and reduced insulin release, but normal
insulin sensitivity in vivo [64].
Conclusions
The major soluble core proteins in catecholamine storage
vesicles (CHGA, CHGB, and SCG2) play catalytic roles in
vesiculogenesis. Common genetic variants in these pro-
teins, especially CHGA 3′-UTR C+87T (rs7610), CHGB
promoter A-296C (rs236140) and A-261T (rs236141), and
SCG2 intronic variant G736A (rs1017448), seem to exert
functional and interactive effects, first on early, “interme-
diate,” or pathogenic phenotypes and finally on basal/
resting BP in the population, leading to risk of hyperten-
sion. SNP-by-SNP interactions, either local (haplotypes) or
distant, may also play roles in the progression of BP. These
results point to new molecular strategies for probing
autonomic control of the circulation and ultimately the
susceptibility to and pathogenesis of cardiovascular disease
states such as hypertension.
Acknowledgment These authors have received support from the US
Department of Veterans Affairs and the National Institutes of Health
(HL58120, RR00827, MD000220).
Disclosure No conflicts of interest relevant to this article were
reported.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
1. Mahapatra NR, Mahata M, Mahata SK, O’Connor DT: The
chromogranin A fragment catestatin: specificity, potency and
mechanism to inhibit exocytotic secretion of multiple catecholamine
storage vesicle co-transmitters. J Hypertens 2006, 24:895–904.
2. Videen JS, Mezger MS, Chang YM, O’Connor DT: Calcium and
catecholamine interactions with adrenal chromogranins. Compar-
ison of driving forces in binding and aggregation. J Biol Chem
1992, 267:3066–3073.
3. Mahapatra NR, O’Connor DT, Vaingankar SM, et al.: Hyperten-
sion from targeted ablation of chromogranin A can be rescued by
the human ortholog. J Clin Invest 2005, 115:1942–1952.
4. Yoo SH, So SH, Huh YH, Park HY: Inositol 1,4,5-trisphosphate
receptor/Ca(2+) channel modulatory role of chromogranins A and
B. Ann N Y Acad Sci 2002, 971:300–310.
5. Mahata SK, Kozak CA, Szpirer J, et al.: Dispersion of
chromogranin/secretogranin secretory protein family loci in
mammalian genomes. Genomics 1996, 33:135–139.
6. Huh YH, Jeon SH, Yoo SH: Chromogranin B-induced secretory
granule biogenesis: comparison with the similar role of chromog-
ranin A. J Biol Chem 2003, 278:40581–40589.
7. Kim T, Tao-Cheng JH, Eiden LE, Loh YP: Chromogranin A, an
“on/off” switch controlling dense-core secretory granule biogen-
esis. Cell 2001, 106:499–509.
8. Beuret N, Stettler H, Renold A, et al.: Expression of regulated
secretory proteins is sufficient to generate granule-like structures in
constitutively secreting cells. J Biol Chem 2004, 279:20242–20249.
9. Taupenot L, Harper KL, O’Connor DT: The chromogranin-
secretogranin family. N Engl J Med 2003, 348:1134–1149.
10. Tatemoto K, Efendic S, Mutt V, et al.: Pancreastatin, a novel
pancreatic peptide that inhibits insulin secretion. Nature 1986,
324:476–478.
Curr Hypertens Rep (2011) 13:36–45 4311. Zhang K, Rao F, Wen G, et al.: Catecholamine storage vesicles
and the metabolic syndrome: The role of the chromogranin A
fragment pancreastatin. Diabetes Obes Metab 2006, 8:621–633.
12. Strub JM, Hubert P, Nullans G, et al.: Antibacterial activity of
secretolytin, a chromogranin B-derived peptide (614–626), is
correlated with peptide structure. FEBS Lett 1996, 379:273–278.
13. Aardal S, Helle KB, Elsayed S, et al.: Vasostatins, comprising the
N-terminal domain of chromogranin A, suppress tension in
isolated human blood vessel segments. J Neuroendocrinol 1993,
5:405–412.
14. Mahata SK, O’Connor DT, Mahata M, et al.: Novel autocrine
feedback control of catecholamine release. A discrete chromogranin
a fragment is a noncompetitive nicotinic cholinergic antagonist. J
Clin Invest 1997, 100:1623–1633.
15. Mahata SK, Mahata M, Parmer RJ, O’Connor DT: Desensitization
of catecholamine release. The novel catecholamine release-
inhibitory peptide catestatin (chromogranin a344-364) acts at the
receptor to prevent nicotinic cholinergic tolerance. J Biol Chem
1999, 274:2920–2928.
16. Benjannet S, Leduc R, Adrouche N, et al.: Chromogranin B
(secretogranin I), a putative precursor of two novel pituitary
peptides through processing at paired basic residues. FEBS Lett
1987, 224:142–148.
17. Benjannet S, Leduc R, Lazure C, et al.: GAWK, a novel human
pituitary polypeptide: isolation, immunocytochemical localization
and complete amino acid sequence. Biochem Biophys Res
Commun 1985, 126:602–609.
18. Kroesen S, Marksteiner J, Leitner B, et al.: Rat brain: distribution of
immunoreactivity of PE-11, a peptide derived from chromogranin B.
Eur J Neurosci 1996, 8:2679–2689.
19. Metz-Boutigue MH, Goumon Y, Lugardon K, et al.: Antibacterial
peptides are present in chromaffin cell secretory granules. Cell
Mol Neurobiol 1998, 18:249–266.
20. Strub JM, Garcia-Sablone P, Lonning K, et al.: Processing of
chromogranin B in bovine adrenal medulla. Identification of
secretolytin, the endogenous C-terminal fragment of residues 614-
626 with antibacterial activity. Eur J Biochem 1995, 229:356–368.
21. Wiedermann CJ: Secretoneurin: a functional neuropeptide in
health and disease. Peptides 2000, 21:1289–1298.
22. Takiyyuddin MA, Baron AD, Cervenka JH, et al.: Suppression of
chromogranin-A release from neuroendocrine sources in man:
pharmacologicalstudies.JClinEndocrinolMetab1991,72:616–622.
23. Dimsdale JE, O’Connor DT, Ziegler M, Mills P: Chromogranin A
correlateswith norepinephrine releaserate. Life Sci 1992, 51:519–525.
24. Takiyyuddin MA, Parmer RJ, Kailasam MT, et al.: Chromogranin
A in human hypertension. Influence of heredity. Hypertension
1995, 26:213–220.
25. Sanchez-Margalet V, Valle M, Lobon JA, et al.: Plasma
pancreastatin-like immunoreactivity correlates with plasma nor-
epinephrine levels in essential hypertension. Neuropeptides 1995,
29:97–101.
26. Sanchez-Margalet V, Valle M, Lobon JA, et al.: Increased
plasma pancreastatin-like immunoreactivity levels in non-obese
patients with essential hypertension. J Hypertens 1995, 13:251–
258.
27. O’Connor DT, Kailasam MT, Kennedy BP, et al.: Early decline in
the catecholamine release-inhibitory peptide catestatin in humans
at genetic risk of hypertension. J Hypertens 2002, 20:1335–1345.
28. Rao F, Wen G, Gayen JR, et al.: Catecholamine release-inhibitory
peptide catestatin (chromogranin A(352-372)): naturally occurring
amino acid variant Gly364Ser causes profound changes in human
autonomic activity and alters risk for hypertension. Circulation
2007, 115:2271–2281.
29. O’Connor DT, Takiyyuddin MA, Printz MP, et al.: Catecholamine
storage vesicle protein expression in genetic hypertension. Blood
Press 1999, 8:285–295.
30. Schober M, Howe PR, Sperk G, et al.: An increased pool of
secretory hormones and peptides in adrenal medulla of stroke-
prone spontaneously hypertensive rats. Hypertension 1989,
13:469–474.
31. Fries RS, Mahboubi P, Mahapatra NR, et al.: Neuroendocrine
transcriptome in genetic hypertension: multiple changes in
diverse adrenal physiological systems. Hypertension 2004,
43:1301–1311.
32. Greenwood TA, Cadman PE, Stridsberg M, et al.: Genome-wide
linkage analysis of chromogranin B expression in the CEPH
pedigrees: implications for exocytotic sympathochromaffin secretion
in humans. Physiol Genomics 2004, 18:119–127.
33. Greenwood TA, Rao F, Stridsberg M, et al.: Pleiotropic effects of
novel trans-acting loci influencing human sympathochromaffin
secretion. Physiol Genomics 2006, 25:470–479.
34. Takiyyuddin MA, De Nicola L, Gabbai FB, et al.: Catecholamine
secretory vesicles. Augmented chromogranins and amines in
secondary hypertension. Hypertension 1993, 21:674–679
35. Lillie EO, O’Connor DT: Early phenotypic changes in hypertension:
a role for the autonomic nervous system and heredity. Hypertension
2006, 47:331–333.
36. Kirchmair R, Gander R, Egger M, et al.: The neuropeptide
secretoneurin acts as a direct angiogenic cytokine in vitro and in
vivo. Circulation 2004, 109:777–783.
37. Boomsma D, Busjahn A, Peltonen L: Classical twin studies and
beyond. Nat Rev Genet 2002, 3:872–882.
38. Folkow B: Physiological aspects of primary hypertension. Physiol
Rev 1982, 62:347–504.
39. Zhang L, Rao F, Wessel J, et al.: Functional allelic heterogeneity
and pleiotropy of a repeat polymorphism in tyrosine hydroxylase:
prediction of catecholamines and response to stress in twins.
Physiol Genomics 2004, 19:277–291.
40. Schork NJ, Nath SK, Fallin D, Chakravarti A: Linkage disequilibrium
analysis of biallelic DNA markers, human quantitative trait loci, and
threshold-defined case and control subjects. Am J Hum Genet 2000,
67:1208–1218.
41. Rana BK, Insel PA, Payne SH, et al.: Population-based sample
reveals gene-gender interactions in blood pressure in White
Americans. Hypertension 2007, 49:96–106.
42. Wen G, Mahata SK, Cadman P, et al.: Both rare and common
polymorphisms contribute functional variation at CHGA, a regulator
of catecholamine physiology. Am J Hum Genet 2004, 74:197–207.
43. Halperin E, Eskin E: Haplotype reconstruction from genotype data
using Imperfect Phylogeny. Bioinformatics 2004, 20:1842–1849.
44. • Chen Y, Rao F, Rodriguez-Flores JL, et al.: Common genetic
variants in the chromogranin A promoter alter autonomic activity
and blood pressure. Kidney Int 2008, 74:115–125. The authors
uncovered a transcriptional basis whereby common variants and
haplotypes in the CHGA promoter may be predictive of heritable
changes in autonomic activity and BP.
45. Comings DE, MacMurray JP: Molecular heterosis: a review. Mol
Genet Metab 2000, 71:19–31.
46. • Chen Y, Rao F, Rodriguez-Flores JL, et al.: Naturally occurring
human genetic variation in the 3′-untranslated region of the
secretory protein chromogranin A is associated with autonomic
blood pressure regulation and hypertension in a sex-dependent
fashion. J Am Coll Cardiol 2008, 52:1468–1481. Here the authors
defined the functional activity of common variant C+87T in the 3′-
UTR of the CHGA mRNA, which has been associated with both
BP elevation in the population and risk for hypertensive
(nondiabetic) renal disease.
47. • Zhang K, Rao F, Wang L, et al.: Common functional genetic
variants in catecholamine storage vesicle protein promoter motifs
interact to trigger systemic hypertension. J Am Coll Cardiol 2010,
55:1463–1475. In this report, common variants and haplotypes of
the CHGB promoter were functionally defined in transcriptional
44 Curr Hypertens Rep (2011) 13:36–45assays; such variants were strongly predictive of autonomic
activity and BP in vivo.
48. Cui JS, Hopper JL, Harrap SB: Antihypertensive treatments
obscure familial contributions to blood pressure variation.
Hypertension 2003, 41:207–210.
49. Seasholtz TM, Wessel J, Rao F, et al.: Rho kinase polymorphism
influences blood pressure and systemic vascular resistance in
human twins: role of heredity. Hypertension 2006, 47:937–947.
50. • Rao F, Zhang K, Khandrika S, et al.: Isoprostane, an
“intermediate phenotype” for oxidative stress heritability, risk
trait associations, and the influence of chromogranin B polymor-
phism. J Am Coll Cardiol 2010, 56:1338–1350. A common
variant (C+84A) in the 3′-UTR of the CHGB mRNA was
associated with an “oxidative stress” phenotype: isoprostane
excretion. The variant acted by disrupting an A/U-rich mRNA
stability element.
51. Wen G, Wessel J, Zhou W, et al.: An ancestral variant of
Secretogranin II confers regulation by PHOX2 transcription
factors and association with hypertension. Hum Mol Genet
2007, 16:1752–1764.
52. Pattyn A, Morin X, Cremer H, et al.: Expression and interactions
of the two closely related homeobox genes Phox2a and Phox2b
during neurogenesis. Development 1997, 124:4065–4075.
53. Rao F, WesselJ, Wen G, et al.: Renalalbumin excretion: twin studies
identify influences of heredity, environment, and adrenergic pathway
polymorphism. Hypertension 2007, 49:1015–1031.
54. • Salem RM, Cadman PE, Chen Y, et al.: Chromogranin A
polymorphisms are associated with hypertensive renal disease. J
Am Soc Nephrol 2008, 19:600–614. This was the initial report on
the effect of CHGA polymorphisms on susceptibility to hyperten-
sive renal disease in African Americans. The functional variant
was at position C+87T in the CHGA mRNA.
55. Lillie EO, Mahata M, Khandrika S, et al.: Heredity of endothelin
secretion: human twin studies reveal the influence of polymor-
phism at the chromogranin A locus, a novel determinant of
endothelial function. Circulation 2007, 115:2282–2291.
56. • Chen Y, Mahata M, Rao F, et al.: Chromogranin A regulates
renal function by triggering Weibel-Palade body exocytosis. J Am
Soc Nephrol 2009, 20:1623–1632. The authors found that CHGA
influenced renal function by triggering generalized exocytosis
from Weibel-Palade bodies, the hormone storage granules in
endothelial cells.
57. • Vaingankar SM, Li Y, Biswas N, et al.: Effects of chromogranin
A deficiency and excess in vivo: biphasic blood pressure and
catecholamine responses. J Hypertens 2010, 28:817–825. CHGA
expression displays paradoxic relationships with BP: though
human essential hypertension is associated with elevated plasma
CHGA, targeted ablation of the Chga locus in the mouse also
results in hypertension. In this study, the authors used gene
targeting and replacement to systematically vary the copy number
of CHGA from 0 to 4 copies per diploid genome, and the results
establishedbiphasiceffectsofCHGAcopynumberoncatecholamine
s t o r a g ea n dr e l e a s ea sw e l la so nB P .
58. • Gayen JR, Gu Y, O’Connor DT, Mahata SK: Global disturban-
ces in autonomic function yield cardiovascular instability and
hypertension in the chromogranin a null mouse. Endocrinology
2009, 150:5027–5035. Targeted ablation of the Chga locus results
in systemic hypertension in the mouse; this study defined
widespread effects of such genetic deletion upon both the
sympathetic and parasympathetic branches of the autonomic
nervous system.
59. • Dev NB, Gayen JR, O’Connor DT, Mahata SK: Chromogranin a
and the autonomic system: decomposition of heart rate variability
and rescue by its catestatin fragment. Endocrinology 2010,
151:2760–2768. Adjustment of heart rate upwards or downwards
in response to endogenous and exogenous cues (heart rate
variability, HRV) reflects a healthy autonomic system. After
targeted ablation of the Chga gene in the mouse, HRV declines;
the trait can be “rescued” by replacement of the catestatin
fragment of CHGA.
60. • Gayen JR, Saberi M, Schenk S, et al.: A novel pathway of
insulin sensitivity in chromogranin A null mice: a crucial role for
pancreastatin in glucose homeostasis. J Biol Chem 2009,
284:28498–28509. In the mouse, knockout of the Chga gene
(Chga-/- genotype) results in a peculiar combination of elevated
blood pressure coupled with enhanced insulin sensitivity, especially
in the liver. Chga encodes a dysglycemic fragment, named
“pancreastatin”; administration of this peptide to Chga-/- mice
reversed the insulin sensitivity of the knockout state.
61. • Friese RS, Gayen JR, Mahapatra NR, et al.: Global metabolic
consequences of the chromogranin A-null model of hypertension:
transcriptomic detection, pathway identification, and experimental
verification. Physiol Genomics 2010, 40:195–207. Here the
authors profiled the transcriptome in mice after targeted ablation
of the Chga locus, and thereby identified global patterns of mRNA
expression subserving enhanced insulin sensitivity in this animal
model.
62. • Zhang K, Rao F, Rana BK, et al.: Autonomic function in
hypertension: Role of genetic variation at the catecholamine
storage vesicle protein chromogranin B (CHGB). Circ Cardiovasc
Genet 2009, 2:46–56. Here the authors defined commonly
occurring, natural genetic variation across the human CHGB
locus, including promoter variants predicting elevated BP. In a
complementary study, targeted ablation of the mouse Chgb locus
resulted in systemic hypertension.
63. Diaz-Vera J, Morales YG, Hernandez-Fernaud JR, et al.: Chro-
mogranin B gene ablation reduces the catecholamine cargo and
decelerates exocytosis in chromaffin secretory vesicles. J Neurosci
2010, 30:950–957.
64. Obermuller S, Calegari F, King A, et al.: Defective secretion of
islet hormones in chromogranin-B deficient mice. PLoS One
2010, 5:e8936.
Curr Hypertens Rep (2011) 13:36–45 45